BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27487151)

  • 1. ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients.
    Li Z; Xing X; Shan F; Li S; Li Z; Xiao A; Xing Z; Xue K; Li Z; Hu Y; Jia Y; Miao R; Zhang L; Bu Z; Wu A; Ji J
    Oncotarget; 2016 Aug; 7(34):55449-55457. PubMed ID: 27487151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
    Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
    BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.
    Han ZG; Tao J; Yu TT; Shan L
    Med Sci Monit; 2017 Apr; 23():1999-2006. PubMed ID: 28442702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
    Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
    Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
    Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
    Tecza K; Pamula-Pilat J; Lanuszewska J; Grzybowska E
    Oncotarget; 2016 Oct; 7(41):66790-66808. PubMed ID: 27527855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
    Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
    Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
    J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy.
    Fujita K; Motoyama S; Sato Y; Wakita A; Nagaki Y; Minamiya Y; Miura M
    Esophagus; 2022 Jan; 19(1):146-152. PubMed ID: 34347217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
    Liu YP; Ling Y; Zhang YP; Liu BR
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):256-9. PubMed ID: 21418871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
    J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review.
    Wang Z; Chen JQ; Liu JL; Qin XG; Huang Y
    BMC Gastroenterol; 2012 Sep; 12():137. PubMed ID: 23020798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.
    Kim K; Kang SB; Chung HH; Kim JW; Park NH; Song YS
    Gynecol Oncol; 2008 Dec; 111(3):509-15. PubMed ID: 18851872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.
    De Troia B; Dalu D; Filipazzi V; Isabella L; Tosca N; Ferrario S; Gambaro AR; Somma L; Fasola C; Cheli S; Clementi E; De Francesco D; Falvella FS; Cattaneo MT
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):803-808. PubMed ID: 30796464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
    Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
    Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma].
    Lu JW; Gao CM; Wu JZ; Sun XF; Wang L; Feng JF
    Ai Zheng; 2004 Aug; 23(8):958-62. PubMed ID: 15301724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.